Tvardi Therapeutics Inc 新一代STAT3抑制剂Tti-109一期临床健康受试者顶线数据预计2026年上半年公布

美股速递
Jan 08

Tvardi Therapeutics Inc宣布,其新一代STAT3抑制剂Tti-109的一期临床试验取得重要进展。针对健康志愿者的顶线数据收集工作正按计划推进,预计将于2026年上半年完成。

该研究旨在评估Tti-109的安全性、耐受性及药代动力学特征。STAT3作为关键信号传导蛋白,在多种肿瘤生长中扮演核心角色。Tti-109通过精准抑制STAT3活性,为晚期癌症治疗提供了新思路。

目前临床试验进程符合预期时间表。若数据结果达到预设终点,将为后续针对实体瘤和血液恶性肿瘤的二期研究奠定基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10